|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYBB |
Gene summary for CYBB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYBB | Gene ID | 1536 |
| Gene name | cytochrome b-245 beta chain | |
| Gene Alias | AMCBX2 | |
| Cytomap | Xp21.1-p11.4 | |
| Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | A0A0S2Z3S6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1536 | CYBB | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.29e-04 | 7.69e-01 | 0.159 |
| 1536 | CYBB | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 7.07e-03 | 9.07e-01 | 0.1537 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
| GO:002290017 | Prostate | Tumor | electron transport chain | 76/3246 | 175/18723 | 5.59e-16 | 1.09e-13 | 76 |
| GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
| GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
| GO:007048218 | Prostate | Tumor | response to oxygen levels | 102/3246 | 347/18723 | 1.62e-08 | 5.75e-07 | 102 |
| GO:001003819 | Prostate | Tumor | response to metal ion | 107/3246 | 373/18723 | 3.02e-08 | 9.77e-07 | 107 |
| GO:003629318 | Prostate | Tumor | response to decreased oxygen levels | 94/3246 | 322/18723 | 8.37e-08 | 2.29e-06 | 94 |
| GO:003196017 | Prostate | Tumor | response to corticosteroid | 57/3246 | 167/18723 | 1.11e-07 | 2.94e-06 | 57 |
| GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
| GO:000166618 | Prostate | Tumor | response to hypoxia | 90/3246 | 307/18723 | 1.27e-07 | 3.28e-06 | 90 |
| GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
| GO:007124114 | Prostate | Tumor | cellular response to inorganic substance | 66/3246 | 226/18723 | 6.63e-06 | 1.00e-04 | 66 |
| GO:007145316 | Prostate | Tumor | cellular response to oxygen levels | 54/3246 | 177/18723 | 1.13e-05 | 1.62e-04 | 54 |
| GO:003629416 | Prostate | Tumor | cellular response to decreased oxygen levels | 49/3246 | 161/18723 | 3.02e-05 | 3.62e-04 | 49 |
| GO:007124815 | Prostate | Tumor | cellular response to metal ion | 56/3246 | 197/18723 | 7.26e-05 | 7.65e-04 | 56 |
| GO:009730518 | Prostate | Tumor | response to alcohol | 68/3246 | 253/18723 | 9.02e-05 | 8.88e-04 | 68 |
| GO:007145614 | Prostate | Tumor | cellular response to hypoxia | 45/3246 | 151/18723 | 1.08e-04 | 1.03e-03 | 45 |
| GO:000941017 | Prostate | Tumor | response to xenobiotic stimulus | 110/3246 | 462/18723 | 2.13e-04 | 1.84e-03 | 110 |
| GO:004668615 | Prostate | Tumor | response to cadmium ion | 24/3246 | 68/18723 | 2.85e-04 | 2.32e-03 | 24 |
| GO:007259315 | Prostate | Tumor | reactive oxygen species metabolic process | 63/3246 | 239/18723 | 2.87e-04 | 2.32e-03 | 63 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0502027 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
| hsa0517129 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
| hsa0501027 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
| hsa0541528 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
| hsa0502227 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
| hsa0406626 | Prostate | Tumor | HIF-1 signaling pathway | 41/1791 | 109/8465 | 5.67e-05 | 4.27e-04 | 2.65e-04 | 41 |
| hsa0414527 | Prostate | Tumor | Phagosome | 52/1791 | 152/8465 | 1.19e-04 | 7.42e-04 | 4.60e-04 | 52 |
| hsa0467029 | Prostate | Tumor | Leukocyte transendothelial migration | 41/1791 | 114/8465 | 1.80e-04 | 1.08e-03 | 6.68e-04 | 41 |
| hsa0541729 | Prostate | Tumor | Lipid and atherosclerosis | 65/1791 | 215/8465 | 9.79e-04 | 4.44e-03 | 2.75e-03 | 65 |
| hsa0493322 | Prostate | Tumor | AGE-RAGE signaling pathway in diabetic complications | 33/1791 | 100/8465 | 3.79e-03 | 1.36e-02 | 8.46e-03 | 33 |
| hsa0421721 | Prostate | Tumor | Necroptosis | 46/1791 | 159/8465 | 1.20e-02 | 3.68e-02 | 2.28e-02 | 46 |
| hsa0514023 | Prostate | Tumor | Leishmaniasis | 25/1791 | 77/8465 | 1.35e-02 | 4.10e-02 | 2.54e-02 | 25 |
| hsa0502036 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
| hsa0517137 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
| hsa0501036 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
| hsa0541536 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
| hsa0502236 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
| hsa0406635 | Prostate | Tumor | HIF-1 signaling pathway | 41/1791 | 109/8465 | 5.67e-05 | 4.27e-04 | 2.65e-04 | 41 |
| hsa0414535 | Prostate | Tumor | Phagosome | 52/1791 | 152/8465 | 1.19e-04 | 7.42e-04 | 4.60e-04 | 52 |
| hsa0467037 | Prostate | Tumor | Leukocyte transendothelial migration | 41/1791 | 114/8465 | 1.80e-04 | 1.08e-03 | 6.68e-04 | 41 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYBB | SNV | Missense_Mutation | c.942N>C | p.Lys314Asn | p.K314N | P04839 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CYBB | SNV | Missense_Mutation | novel | c.1636N>G | p.Leu546Val | p.L546V | P04839 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CYBB | SNV | Missense_Mutation | c.862N>G | p.Phe288Val | p.F288V | P04839 | protein_coding | tolerated(0.12) | benign(0.426) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CYBB | insertion | Nonsense_Mutation | novel | c.637_638insAATAATCC | p.Val213GlufsTer2 | p.V213Efs*2 | P04839 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CYBB | insertion | Frame_Shift_Ins | novel | c.1402_1403insT | p.Arg468MetfsTer18 | p.R468Mfs*18 | P04839 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CYBB | insertion | Frame_Shift_Ins | novel | c.1404_1405insTTAGCCAAATATTTCTCTTTTTACTTCCA | p.Asn469LeufsTer43 | p.N469Lfs*43 | P04839 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CYBB | SNV | Missense_Mutation | novel | c.118N>C | p.Phe40Leu | p.F40L | P04839 | protein_coding | tolerated(0.4) | benign(0.01) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYBB | SNV | Missense_Mutation | c.1039N>A | p.Glu347Lys | p.E347K | P04839 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| CYBB | SNV | Missense_Mutation | novel | c.748N>C | p.Glu250Gln | p.E250Q | P04839 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CYBB | SNV | Missense_Mutation | rs781797749 | c.470N>A | p.Arg157Gln | p.R157Q | P04839 | protein_coding | tolerated(0.11) | benign(0.417) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | APIGENIN | APIGENIN | 23786520 | |
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894227 | ||
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894229 | ||
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894225 | ||
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | CHRYSIN | CHRYSIN | 23786520 | |
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | LUTEOLIN | LUTEOLIN | 23786520 | |
| 1536 | CYBB | ION CHANNEL, TRANSPORTER, DRUGGABLE GENOME, ENZYME | inhibitor | 363894226 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |